Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders
• Through the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia. • The new collaboration further expands Boehringer Ingelheim’s circuitry-based approach […]
LIBD in the News: NPR’s All Things Considered
The full story from Jon Hamilton aired September 24, 2020.